Effect of orally administered sulphinpyrazone (Anturan R) on platelet aggregation in vitro

• Published in: Thrombosis research Vol. 18; no. 1; pp. 89 - 99
• Main Authors: Pfister, B., Godbillon, J., Colussi, D., Imhof, P.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Ltd 01.04.1980
• Subjects: Adenosine Diphosphate - pharmacology; Administration, Oral; Adult; Collagen - pharmacology; Drug Tolerance; Epinephrine - pharmacology; Humans; Male; Middle Aged; plasma concentration; platelet aggregation; Platelet Aggregation - drug effects; Sulfinpyrazone - administration & dosage; Sulfinpyrazone - blood; Sulphinpyrazone; Time Factors; Uric Acid - blood; plasma concentration; Sulphinpyrazone; platelet aggregation
• ISSN: 0049-3848; 1879-2472
• DOI: 10.1016/0049-3848(80)90173-5

Platelet-aggregation tests were performed with citrated blood samples obtained from six healthy volunteers who had received,for investigational purposes, the unusually high single oral dose of 800 mg sulphinpyrazone, or placebo. Sulphinpyrazone inhibited collagen- and ADP-induced, but not adrenaline-induced aggregation. The maximum effect was observed after 2–4 hours, and in the case of collagen-induced aggregation the degree of inhibition was 39%. Sulphinpyrazone increased disaggregation after induction of aggregation with ADP. There was a significant correlation between the inhibition of collagen-induced aggregation and the concentration of sulphinpyrazone in the plasma. Plasma uric-acid levels were markedly decreased after treatment with sulphinpyrazone, but this effect was unrelated to the inhibition of aggregation.